EPS for Achillion Pharmaceuticals, Inc. (ACHN) Expected At $-0.18

October 14, 2017 - By Hazel Jackson

 EPS for Achillion Pharmaceuticals, Inc. (ACHN) Expected At $ 0.18
Investors sentiment increased to 1.33 in Q2 2017. Its up 0.31, from 1.02 in 2017Q1. It improved, as 8 investors sold Achillion Pharmaceuticals, Inc. shares while 37 reduced holdings. 21 funds opened positions while 39 raised stakes. 101.03 million shares or 4.27% more from 96.89 million shares in 2017Q1 were reported.
Paloma Partners Management Communication holds 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) or 13,200 shares. Amalgamated Natl Bank reported 14,410 shares. State Bank Of Mellon has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 611,634 shares. Northern holds 0% or 1.43 million shares. Metropolitan Life Company Ny stated it has 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Creative Planning reported 155,830 shares. Nationwide Fund Advisors has 93,443 shares for 0% of their portfolio. Panagora Asset Mgmt Inc holds 0% or 6,978 shares in its portfolio. Morgan Stanley reported 0% stake. Baker Bros Advsr L P owns 1.86 million shares. Barclays Plc has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Wells Fargo And Communications Mn accumulated 219,647 shares. Dafna Capital Lc accumulated 266,500 shares or 0.87% of the stock. South Dakota Inv Council stated it has 843,500 shares. Deutsche Natl Bank Ag holds 1.31M shares or 0% of its portfolio.

Analysts await Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report earnings on November, 2. They expect $-0.18 earnings per share, down 20.00 % or $0.03 from last year’s $-0.15 per share. After $-0.16 actual earnings per share reported by Achillion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 12.50 % negative EPS growth. It closed at $4.59 lastly. It is down 47.61% since October 14, 2016 and is downtrending. It has underperformed by 64.31% the S&P500.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Coverage

Among 10 analysts covering Achillion Pharma (NASDAQ:ACHN), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Achillion Pharma had 22 analyst reports since August 13, 2015 according to SRatingsIntel. On Thursday, February 2 the stock rating was initiated by Ladenburg Thalmann with “Buy”. Maxim Group maintained the shares of ACHN in report on Wednesday, August 9 with “Buy” rating. UBS upgraded Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on Tuesday, September 8 to “Buy” rating. The rating was upgraded by Chardan Capital Markets to “Neutral” on Friday, November 4. The firm earned “Outperform” rating on Friday, February 26 by Robert W. Baird. The firm earned “Hold” rating on Monday, September 11 by Robert W. Baird. The company was maintained on Wednesday, May 4 by Leerink Swann. On Friday, September 23 the stock rating was initiated by Wedbush with “Outperform”. The firm has “Hold” rating by Jefferies given on Wednesday, September 9. The firm has “Market Perform” rating by Leerink Swann given on Friday, January 29.

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $627.74 million. The Firm is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. It currently has negative earnings. The Firm is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Another recent and important Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) news was published by Seekingalpha.com which published an article titled: “Achillion Is Crushed As Johnson & Johnson Heads For The Exit” on September 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com